|Bid||200.00 x 800|
|Ask||200.10 x 800|
|Day's range||198.83 - 202.94|
|52-week range||185.33 - 283.45|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||19.08|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BOSTON, July 28, 2021--Vertex announces initiation of Phase 3 development program for new once-daily triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor).
BOSTON, July 19, 2021--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy surgery with the selective NaV1.8 inhibitor VX-548 and that it expects to commence a second Phase 2 study in acute pain following abdominoplasty surgery in the coming weeks.
BOSTON, July 16, 2021--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2021 financial results on Thursday, July 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).